Allarity Therapeutics, Inc. (ALLR) is a Biotechnology company in the Healthcare sector, currently trading at $1.19. It has a SharesGrow Score of 23/100, indicating a weak investment profile with 0 out of 7 criteria passed.
Valuation: ALLR trades at a trailing Price-to-Earnings (P/E) of -1.5 (S&P 500 average ~25).
Financials: revenue is $320,000, +0%/yr average growth. Net income is $11M (loss), growing at -8.6%/yr. Net profit margin is -3509.7% (negative). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $0 against $10M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.13 (strong liquidity). Debt-to-assets is 0%. Total assets: $18M.
Analyst outlook: 1 / 2 analysts rate ALLR as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 11/100 (Fail), Future 40/100 (Partial), Income 10/100 (Fail).
